Is VERACYTE, INC. a Quality Business?
Analyzing business fundamentals using proven investment principles
Exceptional capital returns and consistent cash generation across all measurement periods
About VERACYTE, INC.
Veracyte Inc. is an American genomic diagnostics company headquartered in South San Francisco, California, that provides genomic tests for cancer diagnosis and treatment decisions. The company's Afirma test helps avoid unnecessary thyroid surgeries by providing molecular analysis of indeterminate thyroid nodule samples, and its Prosigna and Decipher genomic tests guide treatment decisions for breast and prostate cancer patients.
📚 How We Measure Business Quality
The Zyberno Score answers one question: "Is this a quality business worth owning?"
We analyze 16 fundamental metrics across four key dimensions, using principles from
Warren Buffett, Benjamin Graham, Peter Lynch,
and Charlie Munger. Each category is worth 25 points for a total of 100.
This score measures business quality only — not whether the stock is cheap, what return you'll get, or when to buy. For that, see the Valuation Trilogy below.
🎯 Recent Earnings Momentum
A separate, shorter-horizon signal — not part of the long-term quality score above. Standardized Unexpected Earnings (SUE) measures how far VCYT's latest quarter beat or missed its own seasonal earnings trend.
View VCYT's full earnings-surprise history and what this signal means →
💡 Quality Is Only Half the Picture
A high quality score means VCYT shows strong business fundamentals.
But even the best business can be a poor investment at the wrong price.
As Warren Buffett says: "Price is what you pay, value is what you get."
To complete your analysis, examine our Valuation Trilogy:
In the Brina Matrix, VERACYTE, INC. (VCYT) is in Value Trap territory — the stock looks cheap at Margin of Safety +28.30% relative to historical earnings, but the Brina Gap of -14.8% shows the current price still assumes faster growth than the business can actually deliver. The apparent bargain does not hold up on a forward basis.
📈 Price Action Check
Market trend context — not part of the Zyberno Score
The market has been actively rewarding VCYT over the past year. Strong momentum on a quality business usually means the story is already being recognised — check the valuation signals above before paying up. Full momentum analysis →
Conclusion: Is VCYT a Good Stock?
According to Zyberno's analysis, VERACYTE, INC. (VCYT) is a Great Business, earning a Zyberno Score of 83/100.
What drives VCYT's score
Zyberno's analysis of VCYT's fundamentals identifies the following key drivers. An ROE of 8.6% falls below the 10% minimum, indicating weak returns on shareholders' capital. ROIC of 9.0% raises questions about capital allocation efficiency. A net margin of 20.4% is exceptional — VERACYTE, INC. keeps 20 cents of profit from every dollar of revenue after all expenses. With a debt-to-equity ratio of 0.06x, VERACYTE, INC. carries minimal leverage — a sign of financial conservatism that reduces risk in economic downturns. A free cash flow margin of 27.6% is impressive, demonstrating that VERACYTE, INC. converts a significant share of revenue into real cash available to shareholders. Revenue has grown at approximately 20.2% annually over the past five years, reflecting strong business momentum. A Piotroski F-Score of 7/9 indicates generally healthy financial signals.
According to Zyberno's valuation model, at its current price of $43.34, VCYT appears to be moderately undervalued compared to an estimated intrinsic value per share of $60.44, with a margin of safety of 28.3%. Based on current pricing and fundamentals, Zyberno's model estimates a 5-year annual return of 28.3%.
The Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in. VERACYTE, INC.'s Brina Gap is -14.8% — the enterprise value implies the market expects much faster growth than the business can actually deliver based on its return on invested capital and reinvestment rate. This is a strong signal that forward compounding capacity is being significantly overestimated.
Zyberno's score and valuation reflect the direct output of the model — business quality from fundamentals, margin of safety from owner earnings, Brina Gap from the reverse DCF. The numbers are not adjusted toward the current price, analyst ratings, or market sentiment. The score measures the quality of the business. The valuation measures the price you pay for it.
Zyberno Verdict
According to Zyberno's model, VERACYTE, INC. (VCYT) is a quality business requiring caution — a Great Business (83/100) with an apparent Margin of Safety of 28.3%, but a Brina Gap of -14.8% reveals the current price still assumes faster growth than the business can deliver.
❓ Frequently Asked Questions
What does VCYT's Zyberno Score of 83/100 mean?
According to Zyberno's scoring model, a score of 83/100 places VERACYTE, INC. in the Great Business category — exceptional capital returns and consistent cash generation across all measurement periods. Zyberno's model scores 75–100 as excellent, 65–74 as good, 50–64 as average, 30–49 as below average, and below 30 as poor, based on the investment frameworks of Buffett, Graham, Lynch, and Munger. Note that a high quality score measures business fundamentals, not whether the stock is currently priced attractively — for that, see the margin of safety analysis.
What makes a stock "high quality"?
A high-quality stock typically exhibits: strong returns on equity and invested capital (indicating competitive advantages), healthy profit margins, low debt levels, ample liquidity, consistent cash flow generation, and sustainable growth. We analyze 16 key metrics across four categories - Profitability (ROE, ROIC, margins), Financial Strength (debt, liquidity, coverage), Cash Flow Quality (FCF, OCF vs earnings), and Growth & Consistency (revenue/profit trends, Piotroski score) - drawing from the investment philosophies of Buffett, Graham, Lynch, and Munger.
How is the quality score different from a stock rating?
Our quality score measures business fundamentals - how well the company operates, generates profits, and maintains financial health. Unlike analyst "buy/sell" ratings, we don't tell you whether to purchase the stock. A company can have excellent quality (great business) but poor investment potential (if overpriced), or vice versa. For valuation analysis, see our Margin of Safety page.
Why do you use Owner Earnings instead of regular earnings?
Owner Earnings, a concept popularized by Warren Buffett, represents the true cash available to shareholders after maintaining the business. Unlike accounting earnings, which can be manipulated through depreciation schedules and accruals, Owner Earnings = Operating Cash Flow minus Maintenance Capital Expenditures. This gives a clearer picture of what a business actually generates for its owners. Learn more about VCYT's Owner Earnings.
How often is the quality score updated?
Quality scores are recalculated whenever new financial data becomes available, typically after quarterly earnings reports. The underlying metrics (ROE, ROIC, debt ratios, etc.) come from company filings and are updated as soon as they're reported. For the most comprehensive and up-to-date data, visit the full VCYT stock report.
📊 Full VCYT Stock Report
Complete financial data, charts, all 250+ metrics, and detailed analysis for VERACYTE, INC..
🎯 VCYT Earnings Surprise (SUE)
See whether VERACYTE, INC. is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
🔍 Stock Screener
Find more high-quality stocks using our advanced screening tools with custom filters.